Proactive Investors - Run By Investors For Investors

Genprex inks research pact with the University of Texas to study anti-cancer agent Oncoprex

Study will focus on the biotech’s active anti-cancer agent Oncoprex to be administered with immunotherapies
A researcher in a lab
The clinical stage gene therapy company will pay MD Anderson US$2mln to conduct the pre-clinical study

Genprex Inc (NASDAQ:GNPX), a clinical-stage gene-therapy company, inked a pact Thursday with the University of Texas MD Anderson Cancer Center for a study focusing on its active anti-cancer agent Oncoprex, to be administered with immunotherapies and research into other tumor suppressor genes.

As a part of the sponsored research agreement, Genprex will pay MD Anderson US$2mln to conduct the pre-clinical study.

The study is titled “A novel therapeutic approach for the treatment of cancer using a combination of the multifactorial tumor suppressor gene TUSC2 and immunotherapy.” TUSC2 is the active agent in Genprex’s investigational non-small-cell, lung cancer drug candidate Oncoprex.

WATCH: Genprex making strides to take cancer-fighting drug Oncoprex to FDA approval

As the title suggests, the study is intended to develop a new therapeutic approach for the treatment of cancer using a combination of the tumor suppressor gene TUSC2 and immunotherapy, including the immune checkpoint inhibitors anti-PD1 and/or anti CTLA-4.

The study may identify biomarkers that can predict the response to therapy across different cancers.

"This research program will evaluate the ability of TUSC2 gene therapy to synergistically enhance the effect and clinical utility of anti-PD1 and/or anti-CTLA-4 therapies,” said Genprex CEO Rodney Varner. “Identifying biomarkers that can predict response rates for Oncoprex-immunotherapy combinations may allow us to explore the utility of this treatment regimen in a broader array of cancers.”

Varner noted that while immunotherapies represent an important advance in treating cancer, even in “highly immunogenic tumors,” most patients “do not respond to checkpoint inhibition.”

“Combination therapies targeting multiple anti-cancer pathways represent a promising approach to achieving greater response rates, and may also allow the expanded use of immunotherapies in a larger population of cancer patients who are not currently candidates for these treatments,” said Varner.

Shares in Genprex were down by a penny to US$7.09 Thursday morning.

View full GNPX profile View Profile

Genprex, Inc. Timeline

Related Articles

April 17 2019
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year
scientist at petrie dish
May 15 2019
Here we take a closer look at Midatech Pharma PLC (LON:MTPH)
Scientist conducting work
CaPre, a potent form of Omega-3, has been shown to reduce triglycerides, but also lower 'bad cholesterol' levels, and raise 'good' ones

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use